XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Summary

The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

Timeline

Start

2006-01

Primary completion

—

Completion

2008-01

Outcome

Outcome not reported

Stopped: “Alternate study projected to assess imaging endpoints versus clinical endpoints.”

Drugs

Indications